Intradermal administration of viral vaccines

Intradermal administration maybe useful in lowering the cost of vaccination against hepatitis B significantly, and may also be helpful for the rapid induction of antibodies, reversing non‐responsiveness, improving postexposure prophylaxis and immunising immunocompromised people. In addition, delayed type hypersensitivity skin reaction to the vaccine could serve as a useful marker for the acquisition of T helper type 1 immunoreactivity in vivo. However, there are some disadvantages when using intradermal vaccinations, including the requirement for skilful administration, the absence of approval from licensing authorities, the development of local skin reactions and a lower antibody response when 1/10 of the standard vaccine dose is used. This requires that appropriate vaccination regimens, including the correct vaccine dosage, and vaccination schedule are followed. In the future, a similar vaccination strategy might also be applied for the prevention and control of other infectious diseases. © 1998 John Wiley & Sons, Ltd.

[1]  S. Lemon,et al.  Vaccines to prevent viral hepatitis. , 1997, The New England journal of medicine.

[2]  M. Johnston HIV/AIDS Vaccine Development: Challenges, Progress and Future Directions , 1996, Reviews in medical virology.

[3]  F. Chisari,et al.  Long-lasting memory T cell responses following self-limited acute hepatitis B. , 1996, The Journal of clinical investigation.

[4]  H. Sacks,et al.  The Efficacy of Influenza Vaccine in Elderly Persons , 1995, Annals of Internal Medicine.

[5]  A. Langmuir,et al.  The cutter incident , 1995 .

[6]  C. Thompson,et al.  Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? , 1995, Cell.

[7]  U. Spengler,et al.  Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection , 1995, Journal of virology.

[8]  B. Cooper,et al.  Immunization with high-dose intradermal recombinant hepatitis B vaccine in healthcare workers who failed to respond to intramuscular vaccination. , 1995, Infection control and hospital epidemiology.

[9]  H L Robinson,et al.  DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Carter,et al.  Intradermal hepatitis B vaccination in a 300-bed primary care hospital: experience with a recombinant vaccine in a four-dose schedule. , 1993, American journal of infection control.

[11]  G. Poland Hepatitis B Vaccines in Clinical Practice , 1993 .

[12]  S. Kashiwagi,et al.  Eosinophilia after intradermal hepatitis B vaccination , 1993, The Lancet.

[13]  H. Bernstein,et al.  Immunization of adults. , 1993, The New England journal of medicine.

[14]  A. Vitiello,et al.  Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein , 1993, Journal of virology.

[15]  J. Ulmer,et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.

[16]  R. Ellis Hepatitis B Vaccines in Clinical Practice , 1992 .

[17]  K. Rao,et al.  Immune response to hepatitis B virus surface antigen peptides during HBV infection , 1992, Clinical and experimental immunology.

[18]  H. Erlich,et al.  Genetic control of nonresponsiveness to hepatitis B virus vaccine by an extended HLA haplotype , 1992, European journal of immunology.

[19]  P. Perine,et al.  Low-dose intradermal and intramuscular vaccination against hepatitis B. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  H. Margolis,et al.  Intradermal hepatitis B vaccination in a large hospital employee population. , 1991, Vaccine.

[21]  S. Kashiwagi,et al.  Cost effectiveness of intradermal vs. subcutaneous hepatitis B vaccination for the mentally handicapped. , 1991, The Journal of infection.

[22]  S. Kashiwagi,et al.  Reversal of nonresponders and postexposure prophylaxis by intradermal hepatitis B vaccination in Japanese medical personnel. , 1991, JAMA.

[23]  T. Mosmann,et al.  The role of IL-10 in crossregulation of TH1 and TH2 responses. , 1991, Immunology today.

[24]  A. Morton,et al.  Comparative trial of low-dose, intradermal, recombinant- and plasma-derived hepatitis B vaccines. , 1990, The Journal of infectious diseases.

[25]  D. Fishbein,et al.  Postexposure prophylaxis for rabies with antiserum and intradermal vaccination , 1990, The Lancet.

[26]  E. Lewis,et al.  Intradermal inoculation with Heptavax-B. Immune response and histologic evaluation of injection sites. , 1989, JAMA.

[27]  E. Caul,et al.  Comparison of intradermal and intramuscular hepatitis B vaccination in university students. , 1989, Vaccine.

[28]  A. Katz,et al.  Genetic prediction of nonresponse to hepatitis B vaccine. , 1989, The New England journal of medicine.

[29]  J. Dienstag Passive‐active immunoprophylaxis after percutaneous exposure to hepatitis B virus , 1989, Hepatology.

[30]  K. Masuko,et al.  Combined hepatitis B immune globulin and vaccine for postexposure prophylaxis of accidental hepatitis B virus infection in hemodialysis staff members: Comparison with immune globulin without vaccine in historical controls , 1989, Hepatology.

[31]  S. Kashiwagi,et al.  Intradermal hepatitis B vaccination for mentally retarded patients. , 1989, The Journal of infection.

[32]  S. Kashiwagi,et al.  Delayed‐Type Hypersensitivity Skin Reaction to HBsAg and Immunohistopathologic Study of Liver in Patients with Acute Type B Viral Hepatitis , 1989, Microbiology and immunology.

[33]  D. Lancaster,et al.  Immunogenisity of the intradermal route of hepatitis B vaccination with the use of recombinant hepatitis B vaccine , 1989 .

[34]  J. Lunn INTRADERMAL HEPATITIS B VACCINE , 1989, The Lancet.

[35]  S. Schalm,et al.  Low‐dose (2 μg) hepatitis B vaccination in medical students: Comparable immunogenicity for intramuscular and intradermal routes , 1989 .

[36]  S. Kashiwagi,et al.  REVERSAL BY INTRADERMAL HEPATITIS B VACCINATION OF UNRESPONSIVENESS TO HBsAg , 1987, The Lancet.

[37]  K. Yamanishi,et al.  Specificity of skin test with varicella-zoster virus antigen in varicella-zoster and herpes simplex virus infections , 1987, Journal of clinical microbiology.

[38]  W. Irving,et al.  ENTRADERMAL HEPATITIS B VACCINE , 1987, The Lancet.

[39]  Roger Williams,et al.  PROSPECTIVE STUDY OF CELLULAR IMMUNITY TO HEPATITIS-B-VIRUS ANTIGENS FROM THE EARLY INCUBATION PHASE OF ACUTE HEPATITIS B , 1987, The Lancet.

[40]  H. Whittle,et al.  Trials of intradermal hepatitis B vaccines in Gambian children. , 1987, Annals of tropical paediatrics.

[41]  A. Zuckerman APPRAISAL OF INTRADERMAL IMMUNISATION AGAINST HEPATITIS B , 1987, The Lancet.

[42]  W. Irving,et al.  INTRADERMAL VACCINATION AGAINST HEPATITIS B , 1986, The Lancet.

[43]  C. Kunz,et al.  Different immune responses after intradermal and intramuscular administration of vaccine against tick‐borne encephalitis virus , 1986, Journal of medical virology.

[44]  E. Prasetya,et al.  Intradermal vaccination against hepatitis B in Immanuel Hospital personnel--a preliminary report. , 1986, Annals of the Academy of Medicine, Singapore.

[45]  P. LaRussa,et al.  Determination of immunity to varicella-zoster virus by means of an intradermal skin test. , 1986, The Journal of infectious diseases.

[46]  W. Bancroft,et al.  Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. A cost reduction strategy. , 1985, JAMA.

[47]  S. Kashiwagi,et al.  Delayed type hypersensitivity (DTH) skin reaction to hepatitis B surface antigen (HBsAg) in patients with type B acute and chronic hepatitis. , 1985, Clinical and experimental immunology.

[48]  S. Nagafuchi,et al.  Development of DTH Skin Reaction to HBsAg in Individuals Immunized with HB Vaccine , 1984, Microbiology and immunology.

[49]  M. Roggendorf,et al.  IMMUNE RESPONSE TO SINGLE DOSE, MULTISITE, INTRADERMAL AND TO INTRAMUSCULAR ADMINISTRATION OF VACCINE AGAINST TICK-BORNE ENCEPHALITIS VIRUS , 1984, The Lancet.

[50]  M. J. Burridge,et al.  Intradermal immunization with human diploid cell rabies vaccine: serological and clinical responses of immunized persons to intradermal booster vaccination. , 1984, American journal of public health.

[51]  D. Warrell,et al.  MULTI-SITE INTRADERMAL AND MULTI-SITE SUBCUTANEOUS RABIES VACCINATION: IMPROVED ECONOMICAL REGIMENS , 1984, The Lancet.

[52]  F. Deinhardt,et al.  ANTIBODY RESPONSES AND SKIN REACTIVITY AFTER INTRADERMAL HEPATITIS B VIRUS VACCINE , 1984, The Lancet.

[53]  Lauchlan B. McKenzie Immunization against hepatitis B , 1984, The Medical journal of Australia.

[54]  S. Kashiwagi,et al.  Development of Skin Reaction to Hepatitis B Vaccines in Man , 1984, Microbiology and immunology.

[55]  D. Francis,et al.  INTRADERMAL HEPATITIS B VIRUS VACCINE: IMMUNOGENICITY AND SIDE-EFFECTS IN ADULTS , 1983, The Lancet.

[56]  S. Davis,et al.  Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[57]  B. Moss,et al.  Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen , 1983, Nature.

[58]  G. Walker,et al.  ESSENTIAL DRUGS FOR PRIMARY-HEALTHCARE STANDARD PACKAGES , 1982, The Lancet.

[59]  K. Nicholson,et al.  MULTISITE INTRADERMAL ANTIRABIES VACCINATION , 1981, The Lancet.

[60]  K. Isselbacher,et al.  Therapy for acute and chronic hepatitis. , 1981, Archives of internal medicine.

[61]  T. Ozaki,et al.  Soluble skin test antigen of varicella-zoster virus prepared from the fluid of infected cultures. , 1981, The Journal of infectious diseases.

[62]  J. Hoofnagle,et al.  Passive-active immunity from hepatitis B immune globulin. Reanalysis of a Veterans Administration cooperative study of needle-stick hepatitis. The Veterans Administration Cooperative Study Group. , 1979, Annals of internal medicine.

[63]  M. Goldfield,et al.  A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 (swine flu) and A/Victoria/75: report of a study and review of the literature. , 1979, American journal of public health.

[64]  R. Larke,et al.  Comparison of responses to influenza A/New Jersey/76-A/Victoria/75 virus vaccine administered intradermally or subcutaneously to adults with chronic respiratory disease. , 1979, The Journal of infectious diseases.

[65]  J. Senior,et al.  Hepatitis B immune globulin for accidental exposures among medical personnel: final report of a multicenter controlled trial. , 1978, The Journal of infectious diseases.

[66]  H. Yabuuchi,et al.  Studies with live varicella vaccine and inactivated skin test antigen: protective effect of the vaccine and clinical application of the skin test. , 1978, Pediatrics.

[67]  R. Purcell,et al.  Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study. , 1978, Annals of internal medicine.

[68]  R. Couch,et al.  The immunizing effect of influenza A/New Jersey/76 (Hsw1N1) virus vaccine administered intradermally and intramuscularly to adults. , 1977, The Journal of infectious diseases.

[69]  H. Kamiya,et al.  Diagnostic skin test reactions with varicella virus antigen and clinical application of the test. , 1977, The Journal of infectious diseases.

[70]  K. Nicholson,et al.  HUMAN DIPLOID CELL STRAIN RABIES VACCINE , 1976, The Lancet.

[71]  M. Eastwood,et al.  NEUTROPHIL FUNCTION AND MYELOPEROXIDASE ACTIVITY IN INFLAMMATORY BOWEL DISEASE , 1976, The Lancet.

[72]  S. Andersson,et al.  Letter: Electro-acupuncture and pain threshold. , 1973, Lancet.

[73]  M. Shearn,et al.  VIRUS-LIKE STRUCTURES IN SJÖGREN'S SYNDROME , 1970 .

[74]  J. Bonner,et al.  Differentiation , 1968, Nature.

[75]  Samson Hh QUALIFICATION AS CONSULTANT. , 1963 .

[76]  A. Sabin,et al.  Studies on variants of poliomyelitis virus. I. Experimental segregation and properties of avirulent variants of three immunologic types. , 1954 .

[77]  B. L. Bennett,et al.  Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines. , 1954, American journal of public health and the nation's health.

[78]  L. Åhman,et al.  Non-efficacy of low-dose intradermal vaccination against hepatitis B in Down's syndrome. , 1993, Scandinavian journal of infectious diseases.

[79]  F. Chisari Hepatitis B virus biology and pathogenesis. , 1992, Molecular genetic medicine.

[80]  O. Weiland,et al.  Intramuscular versus intradermal administration of a recombinant hepatitis B vaccine: a comparison of response rates and analysis of factors influencing the antibody response. , 1992, Scandinavian journal of infectious diseases.

[81]  S. Kashiwagi,et al.  Complete seroconversion by low-dose intradermal injection of recombinant hepatitis B vaccine in hemodialysis patients. , 1991, Nephron.

[82]  Y. Hsu Inadequate immune response among public safety workers receiving intradermal vaccination against hepatitis B--United States, 1990-1991. , 1991, MMWR. Morbidity and mortality weekly report.

[83]  D. Lancaster,et al.  Immunogenicity of the intradermal route of hepatitis B vaccination with the use of recombinant hepatitis B vaccine. , 1989, American journal of infection control.

[84]  F. Deinhardt,et al.  Evaluation of a reduced dose of hepatitis B vaccine administered intradermally , 1984, Journal of medical virology.